Humanization and Characterization of an Anti-Ricin Neutralization Monoclonal Antibody

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Hu, Wei Gang ^a   Yin, Junfei ^a   Chau, Damon ^a   Negrych, Laurel M ^a   Cherwonogrodzky, John W ^a  

^a DEFENCE RESEARCH AND DEVELOPMENT CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY D9; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; RICIN; RICIN ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY COMBINING SITE; ANTIBODY GENE; ANTIBODY RESPONSE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DNA PURIFICATION; DNA SEQUENCE; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; GENE; GENETIC RECOMBINATION; HUMAN; IN VIVO STUDY; LD 50; LOW DRUG DOSE; MAMMAL CELL; MOUSE; NONHUMAN; OPEN READING FRAME; PROMOTER REGION; PROTEIN EXPRESSION; SEQUENCE ALIGNMENT; STRUCTURE ANALYSIS;

ADENOVIRIDAE; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY AFFINITY; ANTITOXINS; CHEMICAL WARFARE AGENTS; COMPLEMENTARITY DETERMINING REGIONS; DNA, VIRAL; FEMALE; FOOT-AND-MOUTH DISEASE VIRUS; GENETIC VECTORS; HALF-LIFE; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; INJECTIONS, INTRAPERITONEAL; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PLANT POISONING; PROTEIN ENGINEERING; RICIN; SURVIVAL RATE;

FOOT-AND-MOUTH DISEASE VIRUS; MAMMALIA; MURINAE; MUS;

EID: 84866876338     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045595     Document Type: Article

References (50)

1. Montanaro L, Sperti S, Stirpe F, (1973) Inhibition by ricin of protein synthesis in vitro. Ribosomes as the target of the toxin. Biochem J 136: 677-683.
2. Nicolson GL, Lacorbiere M, Hunter TR, (1975) Mechanism of cell entry and toxicity of an affinity- purified lectin from Ricinus communis and its differential effects on normal and virus-transformed fibroblasts. Cancer Res 35: 144-155.
3. Youle RJ, Colombatti M, (1987) Hybridoma cells containing intracellular anti-ricin antibodies show ricin meets secretory antibody before entering the cytosol. J Biol Chem 262: 4676-4682.
4. Simmons BM, Stahl PD, Russell JH, (1986) Mannose receptor-mediated uptake of ricin toxin and ricin A chain by macrophages. Multiple intracellular pathways for a chain translocation. J Biol Chem 261: 7912-7920.
5. Endo Y, Mitsui K, Motizuki M, Tsurugi K, (1987) The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. The site and the characteristics of the modification in 28 S ribosomal RNA caused by the toxins. J Biol Chem 262: 5908-5912.
6. Audi J, Belson M, Patel M, Schier J, Osterloh J, (2005) Ricin poisoning: a comprehensive review. JAMA 294: 2342-2351.
7. Kantha SS, (1991) A centennial review; the 1890 tetanus antitoxin paper of von Behring and Kitasato and the related developments. Keio J Med 40: 35-39.
8. Mabry R, Rani M, Geiger R, Hubbard GB, Carrion R, et al. (2005) Passive protection against anthrax by using a high-affinity antitoxin antibody fragment lacking an Fc region. Infect Immun 73: 8362-8368.
9. Marks JD, (2004) Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization. Mov Disord 19Suppl 8: S101-108.
10. Binder P, Attre O, Boutin JP, Cavallo JD, Debord T, et al. (2003) Medical management of biological warfare and bioterrorism: place of the immunoprevention and the immunotherapy. Comp Immunol Microbiol Infect Dis 26: 401-421.
11. Reichert JM, (2008) Monoclonal antibodies as innovative therapeutics. Curr Pharm Biotechnol 9: 423-430.
12. Hu WG, Nagata LP, (2008) Antibody gene-based prophylaxis and therapy for biodefence. Hum Vaccin 4: 74-78.
13. Prigent J, Panigai L, Lamourette P, Sauvaire D, Devilliers K, et al. (2011) Neutralising antibodies against ricin toxin. PLoS One 6: e20166.
14. Neal LM, O'Hara J, Brey RN, 3rd, Mantis NJ (2010) A monoclonal immunoglobulin G antibody directed against an immunodominant linear epitope on the ricin A chain confers systemic and mucosal immunity to ricin. Infect Immun 78: 552-561.
15. Pelat T, Hust M, Hale M, Lefranc MP, Dubel S, et al. (2009) Isolation of a human-like antibody fragment (scFv) that neutralizes ricin biological activity. BMC Biotechnol 9: 60.
16. O'Hara JM, Neal LM, McCarthy EA, Kasten-Jolly JA, Brey RN, et al. (2010) Folding domains within the ricin toxin A subunit as targets of protective antibodies. Vaccine 28: 7035-7046.
17. Mantis NJ, McGuinness CR, Sonuyi O, Edwards G, Farrant SA, (2006) Immunoglobulin A antibodies against ricin A and B subunits protect epithelial cells from ricin intoxication. Infect Immun 74: 3455-3462.
18. Roche JK, Stone MK, Gross LK, Lindner M, Seaner R, et al. (2008) Post-exposure targeting of specific epitopes on ricin toxin abrogates toxin-induced hypoglycemia, hepatic injury, and lethality in a mouse model. Lab Invest 88: 1178-1191.
19. Wu F, Fan S, Martiniuk F, Pincus S, Muller S, et al. (2010) Protective effects of anti-ricin A-chain antibodies delivered intracellularly against ricin-induced cytotoxicity. World J Biol Chem 1: 188-195.
20. Maddaloni M, Cooke C, Wilkinson R, Stout AV, Eng L, et al. (2004) Immunological characteristics associated with the protective efficacy of antibodies to ricin. J Immunol 172: 6221-6228.
21. Mirick GR, Bradt BM, Denardo SJ, Denardo GL, (2004) A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words. Q J Nucl Med Mol Imaging 48: 251-257.
22. Wang Y, Guo L, Zhao K, Chen J, Feng J, et al. (2007) Novel chimeric anti-ricin antibody C4C13 with neutralizing activity against ricin toxicity. Biotechnol Lett 29: 1811-1816.
23. O'Hara JM, Whaley K, Pauly M, Zeitlin L, Mantis NJ, (2012) Plant-based expression of a partially humanized neutralizing monoclonal IgG directed against an immunodominant epitope on the ricin toxin A subunit. Vaccine 30: 1239-1243.
24. Bruggemann M, Winter G, Waldmann H, Neuberger MS, (1989) The immunogenicity of chimeric antibodies. J Exp Med 170: 2153-2157.
25. Verhoeyen M, Milstein C, Winter G, (1988) Reshaping human antibodies: grafting an antilysozyme activity. Science 239: 1534-1536.
26. Hwang WY, Foote J, (2005) Immunogenicity of engineered antibodies. Methods 36: 3-10.
27. Tsurushita N, Hinton PR, Kumar S, (2005) Design of humanized antibodies: from anti-Tac to Zenapax. Methods 36: 69-83.
28. Hu WG, Chau D, Wu J, Jager S, Nagata LP, (2007) Humanization and mammalian expression of a murine monoclonal antibody against Venezuelan equine encephalitis virus. Vaccine 25: 3210-3214.
29. Hu WG, Jager S, Chau D, Mah D, Nagata LP, (2010) Generation of a recombinant full-length human antibody binding to botulinum neurotoxin A. Appl Biochem Biotechnol. 160: 1206-1216.
30. Hu WG, Phelps AL, Jager S, Chau D, Hu CC, et al. (2010) A recombinant humanized monoclonal antibody completely protects mice against lethal challenge with Venezuelan equine encephalitis virus. Vaccine 28: 5558-5564.
31. Kabat EA, Wu TT, Reid-Miller IJ (1984) Fundamental Immunology. In: Paul WE, editor. New York: Raven Press. 595-644.
32. Chothia C, (1992) Proteins. One thousand families for the molecular biologist. Nature 357: 543-544.
33. Thullier P, Huish O, Pelat T, Martin AC, (2010) The humanness of macaque antibody sequences. J Mol Biol 396: 1439-1450.
34. Padlan EA, (1991) A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties. Mol Immunol 28: 489-498.
35. Hwang WY, Almagro JC, Buss TN, Tan P, Foote J, (2005) Use of human germline genes in a CDR homology-based approach to antibody humanization. Methods 36: 35-42.
36. Tamura M, Milenic DE, Iwahashi M, Padlan E, Schlom J, et al. (2000) Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only. J Immunol 164: 1432-1441.
37. Nussenzweig MC, Alt FW, (2004) Antibody diversity: one enzyme to rule them all. Nat Med 10: 1304-1305.
38. Neuberger MS, Milstein C, (1995) Somatic hypermutation. Curr Opin Immunol 7: 248-254.
39. Wedemayer GJ, Patten PA, Wang LH, Schultz PG, Stevens RC, (1997) Structural insights into the evolution of an antibody combining site. Science 276: 1665-1669.
40. Zimmermann J, Oakman EL, Thorpe IF, Shi X, Abbyad P, et al. (2006) Antibody evolution constrains conformational heterogeneity by tailoring protein dynamics. Proc Natl Acad Sci U S A 103: 13722-13727.
41. Riechmann L, Clark M, Waldmann H, Winter G, (1988) Reshaping human antibodies for therapy. Nature 332: 323-327.
42. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, et al. (1992) Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 89: 4285-4289.
43. Chothia C, Lesk AM, (1987) Canonical structures for the hypervariable regions of immunoglobulins. J Mol Biol 196: 901-917.
44. Chothia C, Lesk AM, Tramontano A, Levitt M, Smith-Gill SJ, et al. (1989) Conformations of immunoglobulin hypervariable regions. Nature 342: 877-883.
45. Foote J, Winter G, (1992) Antibody framework residues affecting the conformation of the hypervariable loops. J Mol Biol 224: 487-499.
46. Nakanishi T, Tsumoto K, Yokota A, Kondo H, Kumagai I, (2008) Critical contribution of VH-VL interaction to reshaping of an antibody: the case of humanization of anti-lysozyme antibody, HyHEL-10. Protein Sci 17: 261-270.
47. Takahashi H, Tamura H, Shimba N, Shimada I, Arata Y, (1994) Role of the domain-domain interaction in the construction of the antigen combining site. A comparative study by 1H-15N shift correlation NMR spectroscopy of the Fv and Fab fragments of anti-dansyl mouse monoclonal antibody. J Mol Biol 243: 494-503.
48. Donnelly ML, Luke G, Mehrotra A, Li X, Hughes LE, et al. (2001) Analysis of the aphthovirus 2A/2B polyprotein 'cleavage' mechanism indicates not a proteolytic reaction, but a novel translational effect: a putative ribosomal 'skip'. J Gen Virol 82: 1013-1025.
49. Fang J, Qian JJ, Yi S, Harding TC, Tu GH, et al. (2005) Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol 23: 584-590.
50. Szymczak AL, Workman CJ, Wang Y, Vignali KM, Dilioglou S, et al. (2004) Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat Biotechnol 22: 589-594.